Las Palmas
Las Palmas
Las Palmas, Las Palmas, Spain5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, injury, radiation injury, radiation-induced disorder | Recruiting | Not stated | 2026-09-25 | NCT06816095 | |
| Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544). | Hypesthesia, Neurologic Manifestations, Paresthesia, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Somatosensory Disorders, anxiety disorder, depressive disorder, nervous system disorder, psychiatric disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-25 | NCT06799351 | |
| Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025 | Chronic Pain, Intractable Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, anxiety disorder, depressive disorder, injury, psychiatric disorder, radiation injury | Active, not recruiting | Not stated | 2026-09-25 | NCT05417737 | |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-18 | NCT06767514 | |
| Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy | Hypesthesia, Neurologic Manifestations, Paresthesia, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, Somatosensory Disorders, anxiety disorder, depressive disorder, nervous system disorder, psychiatric disorder | Recruiting | Phase 2 / Phase 3 | 2026-09-18 | NCT06706544 |